drugset
Drugs / MRX-4
last change Nov 2024 re-read 9 days ago

MRX-4

Small molecule

Investigated by
MicuRx · Worldwide Clinical Trials

Trials 2

today NCT03033329 · Ph 1 NCT03033342 · Ph 1
20172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1 NCT03033329 Oct 2016 → Mar 2018 — MicuRx Completed No outcome recorded
Phase 1 NCT03033342 Aug 2016 → Feb 2017 — MicuRx Completed No outcome recorded

News releases announcing trial results or a regulatory action · 4

DateIssuerRelease
2024-11-28 MicuRx Results 盟科药业成功完成注射用MRX-4中国Ⅲ期临床试验 micurx.com ↗
统计学分析显示MRX-4/康替唑胺片治疗复杂性皮肤和软组织感染的临床疗效非劣效于利奈唑胺组，本研究达到主要疗效终点。
2022-10-24 MicuRx Results 盟科药业在2022年美国感染性疾病周（IDWeek 2022）上积极公布研发数据，为多重耐药菌感染治疗助力 micurx.com ↗
数据显示，CZD/CZA在各亚组人群间临床疗效与安全性相似；与同类药物相比，显示出血液学相关安全性优势。
2019-09-09 MicuRx Results 盟科医药宣布新型抗生素康泰唑胺磷酸盐（ Contezolid Acefosamil）在美国开展的针对 ABSSSI的二期临床试验获得积极结果 micurx.com ↗
康泰唑胺磷酸盐达到了所有首要和次要的疗效终点，并显示了更好的血液学安全性。
2018-09-21 MicuRx Regulatory 盟科医药宣布Contezolid和Contezolid acefosamil获得美国FDA的QIDP和Fast Track认定 micurx.com ↗
加州福斯特城和中国上海 -2018年9月21日，盟科医药今天宣布美国食品药品监督管理局（FDA）授予contezolid（MRX-I）和其前药contezolid acefosamil (MRX-4)用于治疗急性细菌皮肤和皮肤组织感染（ABBSSI）的合格感染疾病产品（QIDP）和快速审评（fast track）认定。

All press releases naming this drug 5 releases

DateIssuerRelease

Evidence & citations 3 cited values

Every value below carries the sentence it was read from. 2 sources stand behind the page.

FieldValueCited text
Known as MRX-4 ClinicalTrials.gov intervention name — accepted as the source's own label NCT03033342 ↗
1

NCT03033329 ↗
Modality Small molecule “a new oxazolidinone antibiotic” NCT03033329 ↗
Route Intravenous “Intravenous single escalating doses of MRX-4” NCT03033329 ↗